ET-743 PharmaMar/NCI/Ortho Biotech

Current Opinion in Investigational Drugs

Volumn 2, Issue 11, 2001, Pages 1631-1638

  Verschrasegen, C F ^a   Glover, K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG METABOLISM; DRUG SYNTHESIS; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG CANCER; MELANOMA; NONHUMAN; REVIEW; SOFT TISSUE SARCOMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; HUMANS; ISOQUINOLINES; TETRAHYDROISOQUINOLINES;

EID: 0035182345     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Additional antitumuour ecteinascidins from a Carribbean tunicate: Crystal structures and activities in vivo
2. Ecteinascidins
3. Antitumor lead compounds and drug candidates
4. ET743, a marine natural product with high antitumour activity in human tumour xenograft models
5. Ecteinascidin-743
6. Toxicity of ecteinascidin 743 in female Fischer-344 rats administered iv in a multiple-dose regimen
7. Ecteinascidin-743 24 hours continuous infusion: Clinical and pharmacokinetic phase I study in solid tumor patients. Preliminary results
8. Phase I and pharmacokinetic study of ET-743, a novelminor groove binder of marine origin on a daily × 5 schedule
9. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
10. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
11. DNA minor groove alkylation by Ecteinascidin 743 (E1743) induces sequence specific topoisomerase I-mediated DNA damage
12. American Society of Clinical Oncology - 35th Annual Meeting (Part IV), Atlanta, GA, USA
13. Pharma Mar, SA, research and development overview
14. Pharmacokinetics (PK) and pharmacodynamics (PD) of ET-743 (ecteinascidin-743) in Phase I trials
15. Final results of a phase I study of ecteinascindin-743 (ET-743) 24 hour continuous infusion in advanced solid tumors patients
16. Final results of a phase I and pharmacokinetic study of the marine minor groove binder ET-743 on a daily × 5 schedule
17. Drug derived from marine organisms continues to show favorable results in cancer trials - ET-743 promising development in treatment of sarcoma
18. Ecteinasceidin (ET-743) shows promising activity in distinct populations of sarcoma patients: Summary of 3 U.S.-based phase II trials
19. Ecteinascidin-743 (ET-743) in taxane (T)/anthracycline (A) pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts): Preliminary results with the 24 hour (H) continuous infusion (CI) Q3week schedule
20. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743
21. Corporate profile
22. PharmaMar achieves the hemisynthesis of ET-743, reducing the number of production steps for the drug in half
23. Antitumor agent ecteinascidin 743 (ET743): Characterization of its covalent DNA adducts and biological implications
24. Summary of the American Chemical Society 220th National Meeting, Washington DC, USA
25. Population pharmacokinetics of ecteinascidin 743 patients with advanced soft tissue sarcoma
26. Ecteinascidin 743, a novel chemotherapeutic agent targets transcriptional activation of a subset set of genes, including MDR1
27. Preliminary results of phase II study of ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) q3week schedule in primary treated advanced/metastatic breast cancer (A/MBC) patients (Pts)
28. Nucleotide excision repair-dependent cytotoxicity of ecteinascidin 743
29. EORTC - Pharmacology and Molecular Mechanisms Group 22nd Meeting, New Drugs Discovered in the Last Decade: Vacuous Hype, Future Promise, Neither or Both? Verona, Italy
30. Nucleotide excision repair (XPG)-dependent antiproliferative activity of ecteinascidin 743
31. Search for metabolites of ecteinascidin -743 (ET-743), a novel marine derived anticancer agent
32. American Association for Cancer Research 92nd Annual Meeting (Part X), New Orleans, LA, USA
33. Nucleotide excision repair-mediated cytotoxicity of ecteinascidin 743, a novel anticancer agent in clinical trials
34. Differential effects of the murine compound ET743 on transcription of cell cycle regulated promoters
35. Genetic aberrations of nucleotide excision repair (NER) factors in human sporadic carcinomas
36. Novel marine derived anticancer agents ET-743, Spisulosine (ES-285) and Kahalalide F are not transported by the breast cancer resistance protein
37. Ecteinascidin 743, a novel natural cytotoxic compound, is potent for human neuroblastoma and rhabdomyosarcoma cell lines: Multiple mechanisms of cell kill
38. Activity of ecteinascidin 743 and synergism with Doxorubicin and Vincristine in P-glycoprotein/MDR1 over-expression cell lines
39. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
40. Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity
41. American Society of Clinical Oncology - 37th Annual Meeting - Overnight Report (Part III), San Francisco, CA, USA
42. Marine-derived ET-743 may increase survival for cancer patients - Promising development in treatment of sarcoma
43. Population pharmacokinetics of the novel marine derived anticancer agent ecteinascidin 743 in two phase II studies using non-linear mixed effects modeling (NONMEM)
44. Ecteinascidin given as a 24 hour intravenous continuous infusion every 3 weeks: Result of a phase II trial in patients with pretreated soft tissue sarcomas
45. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmacokinetic studies in the U.S.A.
46. ET-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial
47. PharmaMar's ET-743 receives Orphan Product designation in Europe for the treatment of soft tissue sarcoma
48. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
49. Antitumor compounds from tunicates
50. In vitro activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
51. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
52. Zeltia announces licensing agreement with Ortho Biotech to develop and market new cancer treatment
53. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo
54. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
55. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
56. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
57. Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction
58. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study
59. Pharmacokinetics (PK)/pharmacodynamic (PD) relationships in patients (PT) treated with Ecteinascidin-743 (ET-743) given as 24 hours (h) continuous infusion (CI) (Meeting abstract)
60. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743
61. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
62. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer
63. The NMR model of an ecteinascidin 743-DNA adduct (Meeting abstract)
64. Final results of a phase I and pharmacokinetic (PK) study of the marine minor groove binder ET-743 on a daily X 5 schedule. (Meeting abstract)
65. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
66. Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days (Meeting abstract)
67. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (sts): Final results of phase II and pharmacokinetic studies in the USA
68. ET-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial
69. Ecteinascidin (ET-743) given as a 24 hour (H) intravenous continuous infusion (IVCI) every 3 weeks: Results of a phase II trial in patients (pts) with pretreated soft tissue sarcomas (PSTS)
70. Ecteinascidin-743 (ET-743) in Taxane (T)/Anthracycline (A) pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts): Preliminary results with the 24 hour (H) continuous infusion (CI) Q3week schedule
71. Population pharmacokinetics of the novel marine derived anticancer agent ecteinascidin 743 in two phase II studies using non-linear mixed effects modelling (NONMEM)
72. Final results of a phase I study of ecteinascidin-743 (ET-743) 24 hour (H) continuous infusion (CI) in advanced solid tumors (AST) patients (pts) (Meeting abstract)
73. Phase I and Pharmacokinetics (PK) Study of ET-743, a novel minor groove binder of marine origin on a daily [times] 5 schedule (Meeting abstract)
74. Search for metabolites of ecteinascidin-743 (ET-743), a novel marine derived anticancer agent
75. Zeltia - Johnson & Johnson gets on board